



Where Science Becomes Hope

Patient-Based Panel Discussion Genitourinary Malignancies

- All Speakers: Drs. Brown, Narayan, Berchuck, Carthon, Bilen, Jani, Ciuro
- Case presented by Emory University Hematology-Oncology fellow: Mosun Oyenuga MD MPH

July 25, 2025




EMORY
WINSHIP
CANCER
INSTITUTE
National Cancer Institute-Designated
Comprehensive Cancer Center



**Designated
Comprehensive
Cancer Center**

Case 1

- 73 yo M with MIBC, cisplatin eligible (GFR 55), ECOG 1
- Completed 3C of NAC with ddMVAC in 8/2024
- CtDNA done prior to surgery negative
- Underwent RC/IC following NAC. Path ypT2bN2
- Started on adjuvant Nivo per checkmate 274 trial
- Completed 12 months of treatment and remains on surveillance



CT urogram at diagnosis



CT urogram post RC

Panel discussion

- In patients who are cisplatin eligible, how do you decide options for NAC treatment? ddMVAC vs Gem/Cis vs Gem/Cis/Durva per NIAGARA trial
- if ctDNA was positive prior to surgery, how would this influence the timing of surgery? What are the next steps?
- Is there a role of using ctDNA for surveillance post-surgery in addition to imaging?

Case 2

- 58 yo M with prostate cancer in 2019, Gleason score 4+ 5, 10/12 cores s/p brachytherapy (declined ADT)
- Admitted for back pain in 2022, CT CAP with osseous metastasis in the pelvis, retroperitoneal LNs, and lung. Biopsy of lung confirmed adenocarcinoma, prostate primary
- PET PSMA with diffuse osseous metastasis in the retroperitoneal LNs, rib, vertebral column, and lungs
- Foundation test TMB1, MSS, BRCA 2 mutation noted. Germline testing negative
- Started on triple therapy with ADT, 6C of docetaxel, and darolutamide for high vol dx on PET imaging
- In 2022, rising PSA noted (0.4>8), testosterone 47. PET PSMA with new osseous metastasis in the pelvis consistent with MCRPC
- Started on zoledronic acid and abi/pred. ADT continued

Panel discussion

- At initial diagnosis, how would you have treated this patient with high vol disease? doublet vs triplet therapy? What combinations of therapy would you choose if triplet > abi/pred (PEACE-1) vs darolutamide (ARASENS)
- For this patient, high volume disease was confirmed with PET PSMA not conventional imaging per CHAARTED, can PET PSMA be used to confirm high volume disease?
- Based on the data from the amplitude trial, would you start PARPi as 1L for MCRPC? Any role of using this as 1L in MCSPC? Will you use as a single agent vs combination therapy?
- If mutation was PALB2 or ATM positive? Would you still consider PARPi for treatment?